Cargando…

US public investment in development of mRNA covid-19 vaccines: retrospective cohort study

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group Ltd. 2023
Materias:	Corrections
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10013605/ https://www.ncbi.nlm.nih.gov/pubmed/36918188 http://dx.doi.org/10.1136/bmj.p587

Ejemplares similares

US public investment in development of mRNA covid-19 vaccines: retrospective cohort study
por: Lalani, Hussain S, et al.
Publicado: (2023)

Correction to: The safety of Covid-19 mRNA vaccines: a review
por: Anand, Pratibha, et al.
Publicado: (2021)

Correction to: Proposed Pathogenesis, Characteristics, and Management of COVID-19 mRNA Vaccine-Related Myopericarditis
por: Hajra, Adrija, et al.
Publicado: (2021)

Correction to: Can mRNA Vaccines Turn the Tables During the COVID-19 Pandemic? Current Status and Challenges
por: Sagili Anthony, Deva Priya, et al.
Publicado: (2021)

Public health impact of delaying second dose of BNT162b2 or mRNA-1273 covid-19 vaccine: simulation agent based modeling study
Publicado: (2021)

Advances in COVID-19 mRNA vaccine development
por: Fang, Enyue, et al.
Publicado: (2022)

Reactogenicity of Simultaneous COVID-19 mRNA Booster and Influenza Vaccination in the US
por: Hause, Anne M., et al.
Publicado: (2022)

COVID-19 mRNA vaccines
por: Huang, Qingrui, et al.
Publicado: (2021)

COVID-19 mRNA Vaccination
por: Vered, Livneh, et al.
Publicado: (2022)

Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel
por: Pilishvili, Tamara, et al.
Publicado: (2021)

Coverage and Estimated Effectiveness of mRNA COVID-19 Vaccines Among US Veterans
por: Young-Xu, Yinong, et al.
Publicado: (2021)

Myocarditis following COVID‐19 mRNA (mRNA‐1273) vaccination
por: Chellapandian, Suresh Babu, et al.
Publicado: (2022)

COVID-19 mRNA vaccines: Platforms and current developments
por: Szabó, Gábor Tamás, et al.
Publicado: (2022)

Lipid nanoparticles in the development of mRNA vaccines for COVID-19
por: Wilson, Barnabas, et al.
Publicado: (2022)

Correction to “Hyper inflammatory syndrome following COVID-19 mRNA vaccine in children: A national post-authorization pharmacovigilance study”
por: Ouldali, Naïm, et al.
Publicado: (2022)

Author Correction: Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes
por: Grewal, Ramandip, et al.
Publicado: (2023)

COVID-19 mRNA Vaccines: A Retrospective Observational Pharmacovigilance Study
por: Ferrara, Francesco, et al.
Publicado: (2022)

What a second booster dose of mRNA COVID-19 vaccines tells us
por: Loubet, Paul, et al.
Publicado: (2022)

Shingles and mRNA COVID‐19 vaccine
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Commentary of the mRNA vaccines COVID-19
por: Vitiello, Antonio, et al.
Publicado: (2021)

Myocarditis and COVID-19 mRNA vaccination
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

COVID-19 mRNA Vaccine and Myocarditis
por: Singh, Balraj, et al.
Publicado: (2021)

COVID‐19 mRNA vaccines and myopericarditis
por: Gnanenthiran, Sonali R., et al.
Publicado: (2022)

Correction to: Absolute and Relative Vaccine Effectiveness of Primary and Booster Series of COVID-19 Vaccines (mRNA and Adenovirus Vector) Against COVID-19 Hospitalizations in the United States, December 2021–April 2022
Publicado: (2023)

The Risk of Autoimmunity Development following mRNA COVID-19 Vaccination
por: Świerkot, Jerzy, et al.
Publicado: (2022)

Reactogenicity to the mRNA-1273 Booster According to Previous mRNA COVID-19 Vaccination
por: Parés-Badell, Oleguer, et al.
Publicado: (2022)

572. Real-world Effectiveness of COVID-19 mRNA Vaccines against Hospitalizations and Deaths in a Retrospective Cohort
por: Vahidy, Farhaan S, et al.
Publicado: (2021)

Correction: Tissue and Process Specific microRNA–mRNA Co-Expression in Mammalian Development and Malignancy
por: Liu, Hongye, et al.
Publicado: (2009)

Safety profile of mRNA vaccines during first 6 months of the US COVID-19 vaccination programme reviewed
Publicado: (2022)

The dawn of mRNA vaccines: The COVID-19 case
por: Verbeke, Rein, et al.
Publicado: (2021)

Myocarditis Associated with mRNA COVID-19 Vaccination
por: Starekova, Jitka, et al.
Publicado: (2021)

Myocarditis after Covid-19 mRNA Vaccination
por: Verma, Amanda K., et al.
Publicado: (2021)

Myocarditis following COVID-19 mRNA vaccination
por: Parmar, Kanak, et al.
Publicado: (2021)

COVID-19 mRNA Vaccine-induced Pneumonitis
por: Matsuzaki, Shinichi, et al.
Publicado: (2021)

COVID-19 mRNA Vaccine-Associated Myocarditis
por: Kyaw, Htin, et al.
Publicado: (2022)

mRNA vaccines for COVID-19 and diverse diseases
por: Hussain, Abid, et al.
Publicado: (2022)

mRNA Covid-19 Vaccines in Pregnant Women
por: Riley, Laura E.
Publicado: (2021)

Brief review of the mRNA vaccines COVID-19
por: Vitiello, Antonio, et al.
Publicado: (2021)

Myocarditis following COVID-19 mRNA vaccination
por: Abu Mouch, Saif, et al.
Publicado: (2021)

COVID-19 mRNA vaccination and myocarditis or pericarditis
por: Husby, Anders, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pq3vtmh2vhn5dbnb647s9d7dl4